Impact Biomedical sees $1.12 million in stock sales by Alset Inc.

Impact Biomedical Inc. (NASDAQ:IBO) recently reported significant stock sales by Alset Inc. and its affiliates, as disclosed in a recent SEC filing. On April 2, 2025, and April 3, 2025, Alset Inc. and Alset International Ltd. executed multiple transactions, selling a total of approximately 1.69 million shares of Impact Biomedical’s common stock. The total value of these transactions amounted to $1.12 million, with prices ranging from $0.579 to $0.96 per share. According to InvestingPro data, these transactions occurred amid challenging market conditions, with the stock down nearly 70% in the past week and trading significantly below its 52-week high of $6.17.

Chan Heng Fai Ambrose, the Chairman and CEO of Alset Inc., is the majority shareholder of the company and its subsidiary, Alset International Ltd. Following these transactions, Chan is deemed to be the beneficial owner of 351,555 shares held by Alset International Ltd. The sales were executed in multiple trades, with Alset Inc. and its affiliates providing assurances to furnish full details upon request. InvestingPro analysis indicates the company faces financial challenges, with a weak overall health score and current ratio of 0.25, suggesting potential liquidity concerns. Discover 8 more key insights about IBO’s financial health with an InvestingPro subscription.

In other recent news, Impact BioMedical Inc. has acquired Celios®, an air purification technology firm, in an all-equity deal valued at approximately $1.15 million. This strategic acquisition aims to enhance Impact BioMedical’s health and wellness portfolio and is expected to boost immediate revenue. Celios® is recognized for its advanced air purification systems, which are protected by patents valid through 2043, ensuring exclusivity in the market. The acquisition aligns with Impact BioMedical’s strategy to expand its offerings in innovative health and wellness solutions.

Additionally, Impact BioMedical has addressed recent fluctuations in its stock price, stating there have been no significant business developments that would explain the unusual market activity. The company emphasized its ongoing commitment to developing and patenting new technologies for biopharmaceuticals and consumer healthcare. Despite the notable movements in its stock, no new information has been released that would typically justify such market reactions. Investors and analysts are closely monitoring the situation for any further developments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.